Overview

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cetuximab
Erlotinib Hydrochloride